Business Description

Bristol Myers Squibb Co. is involved in the licensing, development, manufacturing,  distribution, marketing, and sale of biopharmaceutical products. The company offers small molecules or chemically-synthesized drug products produced from biological processes called biologics. The company was established in August 1933. It is headquartered in New York, NY.

Key Financials

Revenue (US$ Mn)

• US$ 46,385 Mn was the annual revenue generated by Bristol Myers Squibb Co. in 2021
• Bristol Myers Squibb Co.’s annual revenue for 2020 was US$ 42,518 Mn, a 62.62% increase from 2019
• From 2018’s annual revenues, Bristol Myers Squibb Co. registered a 15.89% increase in 2019, amounting to US$ 26,145 Mn
• Total revenue of US$ 22,561 Mn was generated in 2018 by Bristol Myers Squibb Co.

Operating Income (US$ Mn)

• Bristol Myers Squibb Co.’s operating income for 2021 was US$ 8,098 Mn, a 271.98% increase from 2020
• The operating income generated by Bristol Myers Squibb Co. in 2020 was US$ 2,177 Mn
• At a 15.53% increase from , Bristol Myers Squibb Co. ‘s operating income of US$ 5,913 Mn was indexed in 2019
• Bristol Myers Squibb Co. generated an operating income of US$ 5,118 Mn in 2018

Net Income (US$ Mn)

• Bristol Myers Squibb Co.’s net income for 2021 was US$ 6,994 Mn, a -177.58% decrease from 2020
• The net income generated by Bristol Myers Squibb Co. in 2020 was US$ -9,015 Mn
• At a -30.1% decrease from , Bristol Myers Squibb Co.’s net income of US$ 3,439 Mn was indexed in 2019
• Bristol Myers Squibb Co. generated a net income of US$ 4,920 Mn in 2018

Operating Margin %

• 17% was the operating margin generated by Bristol Myers Squibb Co. in 2021
• Bristol Myers Squibb Co.’s operating margin for 2020 was 5%, a -77.43% decrease from 2019
• From 2018’s operating margins, Bristol Myers Squibb Co. registered a -0.44% decrease in 2019, amounting to 23%
• An operating margin of 23% was generated in 2018 by Bristol Myers Squibb Co.

Gross Margin %

• Bristol Myers Squibb Co.’s gross margin for 2021 was 79%, an 8.58% increase from 2020
• The gross margin generated by Bristol Myers Squibb Co. in 2020 was 72%
• At a -2.68% decrease from , Bristol Myers Squibb Co.’s gross margin of 69% was indexed in 2019
• Bristol Myers Squibb Co. generated a gross margin of 71% in 2018

SWOT Analysis

Strengths

BMS has a robust focus on research and development (R&D).

R&D activities at the company focus on new products and improvements to existing products via new indications and formulations. Preclinical and clinical research, discovery research, medical support for marketed products, and drug formulation activities are all part of the company’s R&D activities. The company develops medicines that target a variety of diseases, such as immune science, lupus, and inflammatory bowel diseases; oncology including IO; cardiovascular with priority for heart disease; and fibrotic disorder with priority in the lung (IPF and liver).

The company’s R&D pipeline includes potential medicines in a variety of modalities, including small (chemically produced) and large (protein). BMS had 20 compounds in its pipeline at the end of April 2020. It has R&D centers located in India, Belgium, and the US. In order to develop new medicines, it collaborates with many research institutes and organizations around the globe. The company spent US$6,148 million on R&D in FY2019. This accounted for 23.3%. Because the company is focused on R&D, it can develop new products that address the unmet medical needs of a large customer base.

Get this premium content

The Premium data is Locked

Buy Now to Unlock Premium Data

Request Sample Data